Waldenström macroglobulinemia: is newer really better?
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. gertz.morie@mayo.edu
Morie A
MA
Gertz
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D015897:Comorbidity; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007239:Infections / Q000139:chemically induced / Q000453:epidemiology; D020258:Neurotoxicity Syndromes / Q000453:epidemiology / Q000209:etiology; D018570:Risk Assessment; D035703:Therapies, Investigational / Q000009:adverse effects / Q000379:methods / Q000639:trends; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000628:therapy*
D015507:Drugs, Investigational